Quanticate, a global data-focused clinical CRO, has appointed Sally Du Toit as vice president of pharmacovigilance and Chris Cramer as vice president of clinical data management.
“With imminent changes in Pharmacovigilance regulations, our recent partnerships with Medidata RAVE and Comprehend Clinical, the launch of our centralized service provision (CSP) solution, expansion of our India facility, the launch of a new corporate website and significant sales growth, 2012 has become an exciting year for us,” explained David Underwood, Quanticate CEO. “The addition of Sally and Chris will be of great importance in shaping our service as we continue to grow.”
Du Toit, joining Quanticate from her last role as director of pharmacovigilance at Aptiv Solutions, has 27 years industry experience, including experience as a deputy QPPV. She has specific experience in device trials and post-market device vigilance, in addition to extensive experience in both clinical studies and post-marketing surveillance for drugs. Du Toit will lead an experienced team of staff to support the current and future needs of clients.
Cramer is joining Quanticate from PharmaNet, where she was responsible for European data management operations. She brings over 25 years experience in the CRO and pharmaceutical industries, and specific knowledge within late phase trials and electronic data capture solutions.